Frank Yocca - Mar 14, 2023 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Signature
/s/ Javier Rodriguez, as Attorney-in-Fact for Frank Yocca, Ph.D.
Stock symbol
BTAI
Transactions as of
Mar 14, 2023
Transactions value $
-$19,396
Form type
4
Date filed
3/16/2023, 06:01 PM
Previous filing
Jan 24, 2023
Next filing
Jun 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTAI Common Stock Options Exercise +2.08K +24.82% 10.5K Mar 14, 2023 Direct F1
transaction BTAI Common Stock Sale -$19.4K -985 -9.4% $19.69 9.5K Mar 15, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Restricted Stock Units Options Exercise $0 -2.08K -25% $0.00 6.25K Mar 14, 2023 Common Stock 2.08K Direct F1, F4
transaction BTAI Restricted Stock Units Award $0 +9K $0.00 9K Mar 15, 2023 Common Stock 9K Direct F1, F5
transaction BTAI Stock Option (Right to Buy) Award $0 +32K $0.00 32K Mar 15, 2023 Common Stock 32K $19.60 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 23, 2022.
F3 This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.6901 to 19.70. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F5 The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F6 The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 15, 2023 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.